Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3093583rdf:typepubmed:Citationlld:pubmed
pubmed-article:3093583lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0450127lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0205245lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0016263lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0522536lld:lifeskim
pubmed-article:3093583lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:3093583pubmed:issue9lld:pubmed
pubmed-article:3093583pubmed:dateCreated1986-11-18lld:pubmed
pubmed-article:3093583pubmed:abstractTextThe phenotype of T lymphocyte subsets present in renal biopsies showing acute cellular allograft rejection in six patients on cyclosporine have been characterized in situ by immunoperoxidase staining, and after expansion in vitro in interleukin 2 (IL-2) by two-color flow cytometry, sorting, and functional analysis. After 8 to 42 days in organ culture, both Leu-3+ (CD4) and Leu-2+ (CD8) subsets were found in each culture, in a ratio that varied from 0.2 to 5.0, which was not significantly different than the results of in situ immunoperoxidase staining of the uncultured biopsy. The cultured cells were almost all Leu-4+ (CD3) T cells (89% +/- 4), which expressed the activation markers DR (82% +/- 6) and the IL 2 (CD25) receptor (15% +/- 4). The Leu-3+ cells were largely Leu-8- (90% +/- 6), whereas a minority of the Leu-2+ cells were Leu-15+ (CD11) (26% +/- 4). Only a small fraction of the Leu-2+ cells stained for Leu-7 (8% +/- 6). Functional analysis of FACS-purified Leu-2-3+ and Leu-2+3- populations indicated that both subsets proliferated in response to graft donor antigens in a mixed lymphocyte reaction (MLR) and produced IL 2. Only the Leu-2+3- population demonstrated donor-specific cytotoxic activity. A minor subpopulation in each culture were both Leu-3+ and Leu-2+ (2.0%). Leu-2+3+ cells from one biopsy were purified to homogeneity (99.8%), and were found to express the T cell antigen receptor complex Ti/CD3 (WT-31+, Leu-4+), but not the common thymocyte antigen CD1 (OKT6). The Leu-2+3+ cells neither responded in the MLR, nor showed any cytotoxic capacity. The Leu-2+3+ cells were capable of IL 2 but not interferon-gamma production. None of the purified cultures demonstrated NK activity. A subset of the purified Leu-2+3+ cells lost Leu-2+ during 1 to 3 wk in culture, and became Leu-2-3+. These studies provide evidence that the cells that infiltrate renal allografts during rejection include alloproliferative, lymphokine-producing cells of both Leu-2+ and Leu-3+ subsets. The Leu-2+3- cells are also highly cytotoxic against donor lymphocytes, indicating the presence of helper independent cytotoxic T cells. A minor population of Leu-2+3+ T cells that do not express donor specific function was also identified.lld:pubmed
pubmed-article:3093583pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:languageenglld:pubmed
pubmed-article:3093583pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3093583pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3093583pubmed:statusMEDLINElld:pubmed
pubmed-article:3093583pubmed:monthNovlld:pubmed
pubmed-article:3093583pubmed:issn0022-1767lld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:LessoJJlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:ColvinR BRBlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:KurnickJ TJTlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:CosimiA BABlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:PrefferF IFIlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:BoyleL ALAlld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:LazarovitsA...lld:pubmed
pubmed-article:3093583pubmed:authorpubmed-author:TuazonT VTVlld:pubmed
pubmed-article:3093583pubmed:issnTypePrintlld:pubmed
pubmed-article:3093583pubmed:day1lld:pubmed
pubmed-article:3093583pubmed:volume137lld:pubmed
pubmed-article:3093583pubmed:ownerNLMlld:pubmed
pubmed-article:3093583pubmed:authorsCompleteYlld:pubmed
pubmed-article:3093583pubmed:pagination2823-30lld:pubmed
pubmed-article:3093583pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:meshHeadingpubmed-meshheading:3093583-...lld:pubmed
pubmed-article:3093583pubmed:year1986lld:pubmed
pubmed-article:3093583pubmed:articleTitleTwo-color flow cytometry and functional analysis of lymphocytes cultured from human renal allografts: identification of a Leu-2+3+ subpopulation.lld:pubmed
pubmed-article:3093583pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3093583pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3093583pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3093583lld:pubmed